Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.70B | $2.49B | $3.05B | $4.16B | $6.21B | $7.57B | $8.93B | $9.87B | $11.0B | $12.0B |
| Revenue growth | — | 46.2% | 22.5% | 36.6% | 49.1% | 22.1% | 17.9% | 10.5% | 11.7% | 8.9% |
| Operating income | $9.94M | $123M | $635M | $1.20B | $2.86B | $2.78B | $4.31B | $3.83B | -$233M | $4.17B |
| Operating margin | 0.6% | 5.0% | 20.8% | 28.8% | 46.0% | 36.7% | 48.2% | 38.8% | -2.1% | 34.8% |
| Net income | -$112M | $263M | $2.10B | $1.18B | $2.71B | $2.34B | $3.32B | $3.62B | -$536M | $3.95B |
| Net margin | -6.6% | 10.6% | 68.8% | 28.3% | 43.7% | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% |
| EPS (diluted) | -$0.46 | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $236M | $845M | $1.27B | $1.57B | $3.25B | $2.64B | $4.13B | $3.54B | -$493M | $3.63B |
| Capital expenditures | $56.6M | $99.4M | $95.4M | $75.4M | $260M | $235M | $205M | $200M | $298M | $438M |
| Free cash flow | $180M | $746M | $1.17B | $1.49B | $2.99B | $2.41B | $3.93B | $3.34B | -$790M | $3.19B |
| Share buybacks | $0.00 | $0.00 | $350M | $186M | $539M | $1.43B | $0.00 | $428M | $1.18B | $2.02B |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.18B | $1.67B | $2.65B | $3.11B | $5.99B | $6.79B | $10.5B | $10.4B | $4.57B | $5.08B |
| Total assets | $2.90B | $3.55B | $6.25B | $8.32B | $11.8B | $13.4B | $18.2B | $22.7B | $22.5B | $25.6B |
| Total liabilities | $1.56B | $1.50B | $1.81B | $2.23B | $3.06B | $3.33B | $4.24B | $5.15B | $6.12B | $6.98B |
| Shareholders' equity | $1.16B | $2.03B | $4.44B | $6.09B | $8.69B | $10.1B | $13.9B | $17.6B | $16.4B | $18.7B |
| Retained earnings | -$5.37B | -$5.12B | -$2.99B | -$1.85B | $859M | $3.20B | $6.52B | $10.1B | $9.61B | $13.6B |
| Shares (wtd avg diluted) | 245M | 253M | 259M | 261M | 263M | 260M | 259M | 261M | 258M | 258M |
Every figure is extracted from VERTEX PHARMACEUTICALS INC / MA’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.